Liraglutide Protects Kidneys From Ischemia Injury by Blocking Macrophage Traps and Ferroptosis via STAT3/6 Pathway
In 72 mice with renal ischemia-reperfusion injury, liraglutide reduced kidney damage by shifting macrophages from inflammatory M1 to protective M2 type via STAT3/6 signaling, which inhibited macrophage extracellular trap formation and prevented ferroptosis — a specific form of iron-dependent cell death.
Quick Facts
What This Study Found
Liraglutide relieved renal ischemia-reperfusion injury and ferroptosis in vivo. It inhibited macrophage extracellular trap (MET) formation both in vivo and in vitro. Liraglutide decreased STAT1 phosphorylation and increased STAT3/6 phosphorylation, promoting M2 macrophage polarization. STAT3/6 inhibition reversed all liraglutide protective effects.
Key Numbers
72 mice used, 8 per group. Both in vivo kidney injury model and in vitro co-culture system employed.
How They Did This
Animal study: 72 C57BL/6J mice (8 per group) with surgically induced renal ischemia-reperfusion injury. In vitro co-culture of primary tubular epithelium with RAW264.7 macrophages under hypoxia/reoxygenation. METs measured by extracellular DNA, neutrophil elastase, and myeloperoxidase. F4/80 and citH3 immunofluorescence for MET visualization.
Why This Research Matters
Kidney transplantation and major surgery frequently cause ischemia-reperfusion injury, and there are no approved drugs to prevent it. This study identifies a specific, druggable mechanism by which a widely available GLP-1 drug protects the kidneys — through macrophage polarization and ferroptosis prevention — opening a potential new indication for liraglutide.
The Bigger Picture
The discovery that GLP-1 drugs can prevent kidney ischemia injury adds to the growing list of organ-protective effects beyond glucose control. This is particularly relevant for transplant medicine, where protecting the donor kidney during the inevitable ischemia period could improve graft survival.
What This Study Doesn't Tell Us
Mouse model — surgical ischemia in mice doesn't fully replicate human kidney transplantation or acute kidney injury. Liraglutide dosing and timing in the mouse model may not translate directly to clinical use. No long-term kidney function or histology follow-up. RAW264.7 is an immortalized cell line that may not fully represent primary macrophages.
Questions This Raises
- ?Could pretreatment with GLP-1 RAs before kidney transplantation reduce ischemia-reperfusion injury in humans?
- ?Do other GLP-1 RAs (semaglutide, tirzepatide) show similar renoprotective effects through this mechanism?
- ?Is the ferroptosis-prevention mechanism also responsible for the kidney benefits seen in GLP-1 clinical trials?
Trust & Context
- Key Stat:
- M1→M2 macrophage shift Liraglutide switched kidney macrophages from damaging M1 to protective M2 type through STAT3/6 signaling — this shift was essential for preventing kidney injury, as blocking STAT3/6 reversed all protection
- Evidence Grade:
- Rated preliminary: well-designed mechanistic animal study with 72 mice and both in vivo/in vitro confirmation, but no human clinical data.
- Study Age:
- Published in 2024. Addresses the active research area of GLP-1 RA organ protection beyond metabolic effects.
- Original Title:
- Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation.
- Published In:
- International immunopharmacology, 142(Pt B), 113258 (2024)
- Authors:
- Sun, Zejia, Zhang, Feilong, Gao, Zihao, Wu, Jiyue, Bi, Qing, Zheng, Xiang, Zhang, Jiandong, Cao, Peng, Wang, Wei
- Database ID:
- RPEP-09347
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs protect the kidneys during surgery or transplantation?
This mouse study suggests they might. Liraglutide prevented kidney damage from interrupted blood flow (ischemia-reperfusion) by calming inflammatory immune cells and blocking a specific type of cell death called ferroptosis. This is a common problem in kidney transplants, and there's currently no approved drug to prevent it.
What is ferroptosis and why does it matter for kidneys?
Ferroptosis is a recently discovered form of cell death driven by iron and oxidative damage. It's increasingly recognized as a major contributor to kidney injury after blood flow interruption. This study shows liraglutide can prevent ferroptosis by switching inflammatory macrophages to a protective mode — a novel connection between GLP-1 drugs and this cell death pathway.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09347APA
Sun, Zejia; Zhang, Feilong; Gao, Zihao; Wu, Jiyue; Bi, Qing; Zheng, Xiang; Zhang, Jiandong; Cao, Peng; Wang, Wei. (2024). Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation.. International immunopharmacology, 142(Pt B), 113258. https://doi.org/10.1016/j.intimp.2024.113258
MLA
Sun, Zejia, et al. "Liraglutide alleviates ferroptosis in renal ischemia reperfusion injury via inhibiting macrophage extracellular trap formation.." International immunopharmacology, 2024. https://doi.org/10.1016/j.intimp.2024.113258
RethinkPeptides
RethinkPeptides Research Database. "Liraglutide alleviates ferroptosis in renal ischemia reperfu..." RPEP-09347. Retrieved from https://rethinkpeptides.com/research/sun-2024-liraglutide-alleviates-ferroptosis-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.